Thomas A. West - 13 May 2022 Form 4 Insider Report for Intersect ENT, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 May 2022, 18:37:20 UTC
Prior SEC filing
04 Feb 2022
Next SEC filing
08 Jun 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Patrick A. Broderick, Attorney-in-Fact for Thomas A. West

Key filing fact

Thomas A. West filed Form 4 for Intersect ENT, Inc. on 16 May 2022.

Key facts

  • This page summarizes Thomas A. West's Form 4 filing for Intersect ENT, Inc..
  • 7 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 16 May 2022, 18:37.

Change

  • Previous filing in this sequence was filed on 04 Feb 2022.
  • Current net transaction value: -$30,340,952.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$1,121,525
Shares
-39,700
Change %
-11%
Price
$28.25
Shares after
312,048
Date
13 May 2022
Ownership
Direct
Footnotes
F1
XENT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$2,950,882
Shares
-104,456
Change %
-33%
Price
$28.25
Shares after
207,592
Date
13 May 2022
Ownership
Direct
Footnotes
F2
XENT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$5,864,474
Shares
-207,592
Change %
-100%
Price
$28.25
Shares after
0
Date
13 May 2022
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENT transaction Derivative

Stock Options (Right to buy)

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$2,223,275
Shares
-78,700
Change %
-100%
Price
$28.25
Shares after
0
Date
13 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
78,700
Exercise price
$26.18
Footnotes
F4
XENT transaction Derivative

Stock Options (Right to buy)

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$3,346,523
Shares
-118,461
Change %
-100%
Price
$28.25
Shares after
0
Date
13 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
118,461
Exercise price
$23.07
Footnotes
F4
XENT transaction Derivative

Stock Options (Right to buy)

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$2,767,370
Shares
-97,960
Change %
-100%
Price
$28.25
Shares after
0
Date
13 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
97,960
Exercise price
$20.44
Footnotes
F4
XENT transaction Derivative

Stock Options (Right to buy)

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$12,066,903
Shares
-427,147
Change %
-100%
Price
$28.25
Shares after
0
Date
13 May 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
427,147
Exercise price
$20.44
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

Footnote F2

Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

Footnote F5

Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchaser Issuer Common Stock that is subject to performance-based vesting conditions that was outstanding and unexercised and became vested immediately prior to or upon the Effective Time (each, a 'Vested Performance Based Option') was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Performance Based Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Vested Performance Based Option, subject to any required withholding of taxes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .